Mirvaso 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IB/0034/G 
This was an application for a group of variations. 
18/04/2023 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
B.II.e.1.a.2 - Change in immediate packaging of the 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
finished product - Qualitative and quantitative 
composition - Semi-solid and non-sterile liquid 
pharmaceutical forms 
IAIN/0033/G 
This was an application for a group of variations. 
10/02/2023 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IA/0032 
B.III.1.a.2 - Submission of a new/updated or 
09/02/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0031 
B.II.d.2.d - Change in test procedure for the finished 
20/01/2022 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
IB/0030 
C.I.z - Changes (Safety/Efficacy) of Human and 
18/01/2022 
23/01/2023 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10093
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
/202102 
brimonidine (centrally authorised product only) 
IA/0028 
B.III.1.a.2 - Submission of a new/updated or 
07/01/2021 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
PSUSA/10093
Periodic Safety Update EU Single assessment - 
01/10/2020 
n/a 
PRAC Recommendation - maintenance 
/202002 
brimonidine (centrally authorised product only) 
IA/0026 
B.III.1.a.2 - Submission of a new/updated or 
07/02/2020 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
PSUSA/10093
Periodic Safety Update EU Single assessment - 
05/09/2019 
n/a 
PRAC Recommendation - maintenance 
/201902 
brimonidine (centrally authorised product only) 
IB/0025 
C.I.11.z - Introduction of, or change(s) to, the 
09/07/2019 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IAIN/0023 
B.II.b.2.c.1 - Change to importer, batch release 
25/04/2019 
01/04/2020 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
R/0021 
Renewal of the marketing authorisation. 
20/09/2018 
22/11/2018 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II and PL 
the CHMP considered that the benefit-risk balance of 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10093
Periodic Safety Update EU Single assessment - 
06/09/2018 
n/a 
PRAC Recommendation - maintenance 
/201802 
brimonidine (centrally authorised product only) 
IB/0019/G 
This was an application for a group of variations. 
17/05/2018 
n/a 
Mirvaso in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
B.I.d.1.z - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Other 
variation 
B.III.1.a.1 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
II/0017 
Update of section 4.8 of the SmPC in order to update 
26/04/2018 
22/11/2018 
SmPC and PL 
the frequency of the adverse drug reaction (ADR) 
rosacea from “uncommon” to “common” following a 
re-examination of the frequency of ADRs in pertinent 
studies. The package leaflet is updated accordingly. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IA/0018 
B.III.1.a.2 - Submission of a new/updated or 
27/03/2018 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10093
Periodic Safety Update EU Single assessment - 
08/03/2018 
n/a 
PRAC Recommendation - maintenance 
/201708 
brimonidine (centrally authorised product only) 
PSUSA/10093
Periodic Safety Update EU Single assessment - 
01/09/2017 
n/a 
PRAC Recommendation - maintenance 
/201702 
brimonidine (centrally authorised product only) 
IAIN/0015 
B.II.b.1.a - Replacement or addition of a 
15/06/2017 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
PSUSA/10093
Periodic Safety Update EU Single assessment - 
23/03/2017 
24/05/2017 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201608 
brimonidine (centrally authorised product only) 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10093/201608. 
IAIN/0013/G 
This was an application for a group of variations. 
24/03/2017 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0012/G 
This was an application for a group of variations. 
20/02/2017 
24/05/2017 
Annex II and 
PL 
A.5.b - Administrative change - Change in the name 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0011 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
12/01/2017 
24/05/2017 
SmPC, 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
Labelling and 
PL 
IB/0009 
B.II.e.1.b.1 - Change in immediate packaging of the 
16/12/2016 
24/05/2017 
SmPC, 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
Labelling and 
PL 
PSUSA/10093
Periodic Safety Update EU Single assessment - 
15/09/2016 
11/11/2016 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201602 
brimonidine (centrally authorised product only) 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10093/201602. 
PSUSA/10093
Periodic Safety Update EU Single assessment - 
17/03/2016 
n/a 
PRAC Recommendation - maintenance 
/201508 
brimonidine (centrally authorised product only) 
PSUSA/10093
Periodic Safety Update EU Single assessment - 
24/09/2015 
19/11/2015 
SmPC, Annex 
Refer to Scientific conclusions and grounds recommending 
/201502 
brimonidine (centrally authorised product only) 
II and PL 
the variation to terms of the Marketing Authorisation(s)’ for 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10093
Periodic Safety Update EU Single assessment - 
26/03/2015 
02/06/2015 
SmPC and PL 
Please refer to Mirvaso PSUSA-10093-201408 EPAR: 
/201408 
brimonidine (centrally authorised product only) 
Scientific conclusions and grounds recommending the 
variation to the terms of the marketing authorisation. 
PSUSA/10093/201502. 
IAIN/0005 
C.I.8.a - Introduction of or changes to a summary of 
02/02/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IAIN/0003/G 
This was an application for a group of variations. 
14/11/2014 
n/a 
B.III.1.a.1 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0002/G 
This was an application for a group of variations. 
24/09/2014 
02/06/2015 
SmPC, 
B.II.e.1.b.1 - Change in immediate packaging of the 
Labelling and 
PL 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IAIN/0001/G 
This was an application for a group of variations. 
19/03/2014 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
Page 8/8 
 
 
 
 
 
 
 
 
 
 
 
